Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Gross Profit (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Gross Profit for 6 consecutive years, with $32.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit fell 2.28% year-over-year to $32.9 million, compared with a TTM value of $104.5 million through Dec 2025, down 5.98%, and an annual FY2025 reading of $104.5 million, down 5.98% over the prior year.
  • Gross Profit was $32.9 million for Q4 2025 at Cytek Biosciences, up from $27.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $33.7 million in Q4 2024 and bottomed at $14.5 million in Q1 2021.
  • Average Gross Profit over 5 years is $25.3 million, with a median of $25.0 million recorded in 2022.
  • The sharpest move saw Gross Profit skyrocketed 138.75% in 2021, then fell 12.41% in 2025.
  • Year by year, Gross Profit stood at $23.6 million in 2021, then increased by 24.28% to $29.4 million in 2022, then increased by 12.51% to $33.0 million in 2023, then rose by 1.83% to $33.7 million in 2024, then fell by 2.28% to $32.9 million in 2025.
  • Business Quant data shows Gross Profit for CTKB at $32.9 million in Q4 2025, $27.6 million in Q3 2025, and $23.9 million in Q2 2025.